[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390741":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":53,"centralContacts":57,"locations":68,"responsibleParty":85,"collaborators":88,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":10,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":10,"maxAge":10,"enrollmentInfo":101,"targetDuration":10,"studyType":104,"phases":10,"briefSummary":105,"conditions":106,"keywords":10,"overallStatus":71,"whyStopped":10,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Consorci Sanitari de Terrassa","OTHER",[8,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population",null,"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.\n\nNo intervention is performed.",[13,14,15,16,17],"Drug: Antihistamine","Drug: Amantadine","Drug: ACEI","Drug: ARB","Other: Influenza vaccine and COVID",{"label":19,"type":10,"description":20,"interventionNames":21},"Evolution of COVID cases in patients receiving antihistamines","COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines.\n\nNo intervention is performed.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Evolution of COVID cases in patients receiving amantadine.","COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine.\n\nNo intervention is performed.",[14],[27,34,40,45,50],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Antihistamine","No intervention is performed. We propose an observational study.",[19,9],[33],"Antihistamines for COVID",{"type":28,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Amantadine","No intervention is performed. We propose an observational study",[23,9],[39],"Amantadine for COVID",{"type":28,"name":41,"description":30,"armGroupLabels":42,"otherNames":43},"ACEI",[9],[44],"ACEI and COVID",{"type":28,"name":46,"description":30,"armGroupLabels":47,"otherNames":48},"ARB",[9],[49],"ARB and COVID",{"type":6,"name":51,"description":30,"armGroupLabels":52,"otherNames":10},"Influenza vaccine and COVID",[9],[54],{"name":55,"affiliation":5,"role":56},"Anna Puigdellívol-Sánchez, Ph D","PRINCIPAL_INVESTIGATOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":10,"email":62},"Anna Puigdellívol-Sánchez, Ph.D.","CONTACT","34-93-5884555","apuigdellivol@cst.cat",{"name":64,"role":60,"phone":65,"phoneExt":66,"email":67},"Mar Muñoz","34-93-7003657","1895","Reserca@cst.cat",[69],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Hospital de Terrassa","RECRUITING","Terrassa","Barcelona","08227","Spain","ES",{"type":78,"coordinates":79},"Point",[80,81],2.01667,41.56667,{"lat":81,"lon":80},[84],{"name":59,"role":60,"phone":61,"phoneExt":10,"email":62},{"type":56,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Anna Puigdellívol-Sánchez","M.D., Ph.D.",[89,91],{"name":90,"class":6},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"name":92,"class":6},"Institut Català de la Salut","100390741","influenza-vaccination-acei-and-arb-in-the-evolution-of-sars-cov2-infection-100390741",false,"NCT04367883","Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection","Inclusion Criteria:\n\n* Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.\n\nExclusion Criteria:\n\n* None.\n* For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.","ALL",{"count":102,"type":103},3000,"ESTIMATED","OBSERVATIONAL","Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.\n\nOther authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.\n\nThe aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.",[107,108,109,46,110,35],"COVID19","Influenza Vaccination","ACE Inhibitors","Antihistamine Allergy","2026-03-23",{"date":113,"type":114},"2026-03-25","ACTUAL",{"date":116,"type":114},"2020-03-01",{"date":118,"type":103},"2028-02-24",{"name":5,"class":6},1]